24 / 24
Conclusions
•
New effective drugs have opened an abundance of new treatment options
for patients with mPDAC (continuum of care approach)
•
Gem-NABP plus Nal-Iri-5FU is an effective treatment sequence based on
phase III RCT and allows a break from neurotoxicity and eventually a third-
line therapy with platinum analogs
•
After failure to FOLFIRINOX, nab-paclitaxel+gem or gem monotherapy can be
offered (data not based on RCT)
•
Biomarker approach for unique subgroups: MSI high, DNA Repair Deficiency,
NTRK, etc.